Hyperhomocysteinaemia, MTHFR or MTRR Polymorphism and Vitamin Supplementation in Czech Patients Suffering from Cardiovascular Diseases
Hyánek J., Matalon R., Rady P., Szucs S., Šebesta P., Matoušková J., Pejznochová H., Dubská L., Přindisová H., Dvořáková J., Loučka M., Martiniková V., Slancová M.
Metabolic Unit of Dept. Clin. Biochemistry, Dept. Vascular Surgery, Dept. Cardiology and Dept. Radiodiag nostics of Hospital Homolka, Prague, Czech Republic Dept. Paediatrics, Div. Genetics, Univ. of Texas, Galveston, USA Institute of Physics and Statistics High School of Chem. Technology, Prague, Czech Republic |
|
Summary:
In a representative set of 27 Czech patients Suffering from cardiovascular disease with mild hyperhomocysteinaemia (mHHC) (> 20~mo1/1), polymorphisms of MTHFR 677 C > T, MTHFR 1259 and MTRR-Met were followed. The above mentioned patients were selected from a large group of patients (n=5SS4) according to intensity of their clinical and metabolic status. A significantly high incidence of MTHFR 677 C > T polymorphism was observed (p < 0,001). The incidence of other types of polymorphism (MTHFR 1259 and MTRR-Met) was not signiflcantly changed. All hyperhomocysteinaemic patients were supplemented with critical vitamins (i.e. folate, cobalamin and pyridoxine). In 70% of patients with mHHC were folatereversible, 9 % cobalamin: reversible and 6% pyridoxal phosphate-reversible. l5% of patients-resistant to any Supplementation of vitamins are now treated with betaine or riboflavin.
Key words:
Polymorphism of MTHFR and MTRR, Mild Hyperhomocysteinaemia Vitamin Supplementation, Folate, Cobalamin, Pyridoxal Phosphate.
|
